Abstract A 7‐year‐old healthy boy presented with an asymptomatic smooth, firm red plaque on the cheek. Histopathology, immunostaining, molecular testing and imaging confirmed a diagnosis of a primary cutaneous marginal zone B‐cell lymphoma. The lesion was treated with intralesional triamcinolone, with complete clinical resolution achieved within one year. Intralesional steroid injection is an effective first‐line modality for the treatment of patients with limited disease in cosmetically sensitive...
Wed Oct 30, 2019 19:09
Abstract Background Multiple factors affect growth in children with atopic dermatitis (AD). We investigated food restriction practice, nutrition, and growth in children with AD. Food restriction is defined as restriction ≥3 types of food due to AD or food allergy. Methods A cross‐sectional study was performed in 150 children aged 12‐36 months. Exclusion criteria: recurrent infections, moderate to severe asthma, recent systemic steroid, other diseases affecting growth/nutrition. Growth parameters,...
Wed Oct 30, 2019 19:08
Abstract Purpose Intracranial solitary fibrous tumor/hemangiopericytoma (SFT/HPC) and meningioma are difficult to distinguish owing to their overlapping imaging manifestation on routine magnetic resonance imaging. The purpose of this study was to assess whether SFT/HPC can be differentiated from meningioma with diffusion-weighted imaging (DWI) and susceptibility-weighted imaging (SWI). ...
02:00
Abstract Purpose Computed tomography (CT) perfusion (CTP) source images contain both brain perfusion and cerebrovascular information, and may allow a dynamic assessment of collaterals. The purpose of the study was to compare the image quality and the collaterals identified on multiphase CT angiography (CTA) derived from CTP datasets (hereafter called CTPA) reconstructed with iterative model reconstruction (IMR) algorithm in patients with...
Wed Oct 30, 2019 02:00
Abstract Purpose BRAF V600E mutation is a distinctive genomic alteration of pediatric low-grade gliomas with prognostic and therapeutic implications. The aim of this retrospective multicenter study was to analyze imaging features of BRAF V600E-mutant and wild-type cerebral pilocytic astrocytomas (PAs) and gangliogliomas (GGs), focusing on the role of diffusion weighted imaging (DWI). ...
Wed Oct 30, 2019 02:00
TOKYO--(BUSINESS WIRE)--Chugai Pharmaceutical Co., Ltd. (TOKYO : 4519) a annoncé que l’Agence européenne des médicaments (EMA) a accepté la demande d'autorisation de mise sur le marché du satralizumab, (code de développement : SA237), un anticorps de recyclage humanisé anti-récepteur de l'interleukine-6 (IL-6), pour le traitement de patients adultes et adolescents atteints de maladie du spectre de la neuromyélite optique (neuromyelitis optica spectrum disorder, NMOSD). L'EMA a accordé le statut
08:04
TOKIO--(BUSINESS WIRE)--Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519), hat bekannt gegeben, dass die Europäische Arzneimittel-Agentur (EMA) den Zulassungsantrag für Satralizumab (Entwicklungscode: SA237), einen humanisierten, rezyklierenden Interleukin-6- bzw. IL-6-Rezeptor-Antikörper, zur Behandlung von erwachsenen und jugendlichen Patienten mit Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD) entgegengenommen hat. Die EMA hat Satralizumab den Status zur beschleunigten Bearbeitung gewährt. D
08:04
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the pricing of its initial public offering of 3,000,000 shares of common stock at a public offering price of $12.00 per share. In addition, the underwriters have been gran
02:49
SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that it has initiated the Phase 3 LAVENDER placebo-controlled study to evaluate the efficacy and safety of trofinetide for girls and young women with Rett syndrome. Rett syndrome is a serious and rare neurodevelopmental congenital CNS d
Wed Oct 30, 2019 22:15
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis to Announce Third Quarter 2019 Financial Results on November 13, 2019
Wed Oct 30, 2019 22:05
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its third quarter 2019 financial results and provided an update on the company, including its progress with IPI-549, a first-in-class oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective phosphoinositide-3-kinase-gamma (PI3K-gamma) inhibition. “It is an exciting and important time for Infinity as we anticipate completing enrollment in M
Wed Oct 30, 2019 22:03
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2019. Recent developments and highlights include: FDA issued its final guidance document on strategies to mitigate the risk of bacterial contamination in transfused platelet components Total third quarter revenue of $22.8 million Quarterly product revenue of $18.0 million, a 17% increase compared to the prior year quarter Government contract revenue of $
Wed Oct 30, 2019 22:01
LAVAL, Quebec--(BUSINESS WIRE)--Per conto dello sponsor, Acurx Pharmaceuticals, Altasciences è orgogliosa di aver portato a termine con successo la conduzione clinica, la gestione dati e la programmazione SAS per ACX-362E, un nuovo agente antibatterico orale per il trattamento dell'infezione da Clostridioides difficile (CDI), un'infezione intestinale acuta, grave e potenzialmente mortale. Altasciences ha reclutato in modo efficiente e trattenuto 62 soggetti sani e normali per questa sperimentaz
Wed Oct 30, 2019 21:57
OXFORD, England--(BUSINESS WIRE)--Perspectum is excited to unveil new data at The Liver Meeting® 2019, highlighting the diagnostic capabilities of their FDA-cleared imaging products.
Wed Oct 30, 2019 21:56
SANTA CLARA, Calif.--(BUSINESS WIRE)--Cardiva Medical, Inc., an innovator in the field of vascular closure, today announced that positive results from the AMBULATE pivotal study demonstrating the safety and efficacy of the company’s VASCADE® MVP Venous Vascular Closure System compared to manual compression were published online in the Journal of the American College of Cardiology: Clinical Electrophysiology. The company also announced that it has received CE Mark certification in Europe for VAS
Wed Oct 30, 2019 20:57
COLLEGE STATION, Texas--(BUSINESS WIRE)--STATKING Clinical Services, Cincinnati, OH is among the top 100 companies from around the world selected for the 15th annual Aggie 100 List.
Wed Oct 30, 2019 19:53
LAVAL, Quebec--(BUSINESS WIRE)--Altasciences meldet stolz den erfolgreichen Abschluss der klinischen Prüfung, Datenverwaltung und SAS-Programmierung für ACX-362E im Auftrag seines Sponsors Acurx Pharmaceuticals. ACX-362E ist ein neuartiger, oraler, antibakterieller Wirkstoff zur Behandlung der Clostridium difficile-Infektion (CDI), einer akuten, schwerwiegenden und potenziell lebensbedrohlichen Darminfektion. Für diese randomisierte, doppelblinde, placebokontrollierte Erststudie der Phase I am
Wed Oct 30, 2019 18:57
NORTHBROOK, Ill.--(BUSINESS WIRE)--Pamela Landau, Senior Vice President of Integrated Solutions at Continuum Clinical named to PharmaVOICE 100.
Wed Oct 30, 2019 17:24
LAVAL, Québec--(BUSINESS WIRE)--Au nom du sponsor, Acurx Pharmaceuticals, Altasciences est fier d’avoir achevé avec succès la réalisation clinique, la gestion des données et la programmation SAS d’ACX-362E, un nouvel agent de traitement antibactérien oral de l'infection à clostridium difficile (ICD), une infection intestinale aiguë, grave, potentiellement mortelle. Altasciences a efficacement recruté et retenu 62 sujets sains pour ce premier essai à doses multiples ascendantes, randomisé, contr
Wed Oct 30, 2019 17:07
NOTTINGHAM, England--(BUSINESS WIRE)--Tufts white paper indicates Quotient Sciences' Translational Pharmaceutics® platform reduces development times and lowers R&D costs.
Wed Oct 30, 2019 15:00
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD launches SiteCoach training, providing new patient treatment options, accelerating development of life-changing medicines.
Wed Oct 30, 2019 15:00
SEAL BEACH, Calif.--(BUSINESS WIRE)-- #activesurveillance--Dendreon announced early completion of patient enrollment of its Phase 3 ProVent clinical trial.
Wed Oct 30, 2019 15:00
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces New Data Characterizing Genomic Alterations in Thyroid Cancer To Be Presented at American Thyroid Association Annual Meeting
Wed Oct 30, 2019 14:15
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease, today announced that it has signed an agreement with Worldwide Clinical Trials (Worldwide), a leading Contract Research Organization (CRO), to conduct a clinical trial to evaluate safety and efficacy in Alzheimer’s Disease. The trial will evaluate Trappsol® Cyclo™ giv
Wed Oct 30, 2019 14:00
PARAMUS, N.J.--(BUSINESS WIRE)--PGI Drug Discovery LLC (PsychoGenics), announced today that it has received milestone payments from Sunovion Pharmaceuticals Inc. (Sunovion) associated with the advancement of two compounds into clinical testing - SEP-378614 and SEP-380135, bringing the total to four compounds now being studied in clinical trials for people living with neuropsychiatric conditions. "We are pleased to see the continued progress of these compounds that hold promise for people living
Wed Oct 30, 2019 14:00
LAVAL, Quebec--(BUSINESS WIRE)-- #Altasciences--On behalf of the sponsor, Acurx Pharmaceuticals, Altasciences is proud to have successfully completed the clinical conduct, data management, and SAS programming for ACX-362E, a novel, oral antibacterial agent for the treatment of Clostridioides difficile infection (CDI), an acute, serious, potentially life-threatening, intestinal infection. Altasciences efficiently recruited and retained 62 healthy normal subjects for this first-in-human, randomized,...
Wed Oct 30, 2019 13:41
SASKATOON, Saskatchewan--(BUSINESS WIRE)--ZYUS Life Sciences Inc. (“ZYUS”), a company focused on the global development and commercialization of innovative and patient-focused cannabinoid-based therapeutics, announced today that it has entered into a three-year supply agreement with 9869247 Canada Limited ("Stevens Green") pursuant to which ZYUS will purchase high-grade bulk raw cannabis material cultivated and harvested at Stevens Green’s facility in Fort Erie, Ontario. Subject to ZYUS receivi
Wed Oct 30, 2019 13:30
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced that it has completed enrollment in all planned cohorts of the Phase I study of its lead program, ALPN-101, a first-in-class dual ICOS/CD28 antagonist. Alpine will discuss the preliminary findings during its third quarter 2019 company update conference call and webcast sch
Wed Oct 30, 2019 13:30
BARCELONA, España--(BUSINESS WIRE)--Las organizaciones de investigación por contrato (contract research organizations, CRO) están haciendo un progreso considerable en la promoción del avance del sector hacia la mejora del rendimiento de los ensayos clínicos, tal y como lo revela la Veeva 2019 Unified Clinical Operations Survey: Annual CRO Report (Encuesta de operaciones clínicas unificadas Veeva 2019: informe anual de las CRO), uno de los estudios más amplios jamás realizados a nivel mundial en
Wed Oct 30, 2019 13:29
BURLINGTON, Mass.--(BUSINESS WIRE)---- $ARQL #arql--ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the third quarter of 2019. For the quarter ended September 30, 2019, the Company reported a net loss of $10.7 million, or $0.09 per basic share, compared with net loss of $5.6 million, or $0.05 per basic share, for the quarter ended September 30, 2018. As of September 30, 2019, the Company had a total of approximately $174.1 million in cash, cash equivalents, and marketable securities....
Wed Oct 30, 2019 13:00
CAMBRIDGE, Mass., and BEDFORDSHIRE, UK--(BUSINESS WIRE)--Sherlock Biosciences (“Sherlock”), an Engineering Biology company dedicated to making diagnostic testing better, faster and more affordable, and Mologic Ltd, a leading developer of lateral flow and rapid diagnostic technologies, today announced a new collaboration to revolutionize molecular diagnostic testing in low-resource settings and within the home. The work is being facilitated by the Bill & Melinda Gates Foundation through an e
Wed Oct 30, 2019 13:00
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the appointment of David A. Hollander, M.D., M.B.A., as Chief Research & Development Officer, an executive officer position reporting to Vicente Anido, Jr., Ph.D., Aerie’s Chair
Wed Oct 30, 2019 12:30
TOKYO--(BUSINESS WIRE)--Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) ha annunciato che l’Agenzia europea per i medicinali (European Medicines Agency, EMA) ha accettato le richieste di autorizzazione alla commercializzazione per satralizumab (codice di sviluppo: SA237), un anticorpo riciclante umanizzato attivo contro il recettore dell’interleuchina-6 (IL-6), per il trattamento dei pazienti adulti e adolescenti affetti dal disturbo dello spettro della neuromielite ottica (neuromyelitis optica s
Wed Oct 30, 2019 12:20
BETHESDA, Md.--(BUSINESS WIRE)--Today the Cystic Fibrosis Foundation unveiled its Path to a Cure, an ambitious research agenda to deliver treatments for the underlying cause of the disease and a cure for every person with cystic fibrosis (CF). The Foundation is challenging potential collaborators to submit proposals that will accelerate the pace of progress in CF drug discovery and development and intends to allocate half a billion dollars to the effort through 2025. “The CF Foundation has a lo
Wed Oct 30, 2019 12:00
TAIPEI, Taiwan--(BUSINESS WIRE)--Scientific American (November 2019 issue) has published Taiwan Healthcare & Life Sciences Review, a country-focused report presenting a comprehensive insight on biotech ecosystem of Taiwan. It shines the spotlight on Taiwan´s position in the global biotech boom and growing significance which lures attention of worldwide industry players and investors. Along with key government heads, Chairman of the Taipei Exchange (TPEx), Mr. Philip Chen, comments on the vi
Wed Oct 30, 2019 11:26
米カリフォルニア州フォスターシティ & 上海--(BUSINESS WIRE)--（ビジネスワイヤ） -- 非アルコール性脂肪肝炎（NASH）とがんの革新的治療薬の創薬と開発に傾注する世界的バイオ製薬会社のTerns Pharmaceuticals, Inc.は本日、ファルネソイドX受容体（FXR）作動薬である治験薬TERN-101が、NASH治療に向けたファストトラック指定を米国食品医薬品局（FDA）より受けたと発表しました。 Ternsの最高医学責任者（CMO）であるエリン・クワーク（M.D.）は、次のように述べています。「TERN-101のファストトラック指定の取得は、この有望な治療薬を一刻も早く患者に届ける上で重要な前進となるもので、当社は臨床開発を通じてTERN-101を前進させるに当たりFDAとの協力に期待しています。現時点で治療選択肢を持たないNASH患者の未充足ニーズに対応できるTERN-101の可能性を米国FDAが認めたことは、当社にとって喜びです。」 これまでに実施された第1相試験で、TERN-101は1日1回投与と一致する臨床薬物動態特性が実証されました。Ter
Wed Oct 30, 2019 10:29
Abstract Purpose To evaluate the role of diffusion kurtosis and diffusivity as potential imaging biomarkers to predict response to neoadjuvant chemoradiation therapy (CRT) from baseline staging magnetic resonance imaging (MRI) in locally advanced rectal cancer (LARC). Materials and methods This retrospective study included 45 consecutive patients...
08:22
Abstract Purpose To analyze changes in MRI diagnostic accuracy in main rectal tumor (T) evaluation resulting from the use of diffusion-weighted imaging (DWI), according to the degree of experience of the radiologist. Methods This is a cross-sectional study of a database including one hundred 1.5 T MRI records (2011–2016) from patients with biopsy-proven...
08:22
Abstract Evaluation of primary rectal cancer specimens places the pathologist in a unique position relative to peers, as it is one of the few specimens where the report influences not just patient outcomes but also the quality of the surgical technique itself. With ever-increasing data indicating that the completeness of the mesorectal excision and adequate resection margins are critical for reduced local recurrence rates and improved clinical outcome, the pathologist is faced...
08:22
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου